Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
GORTEC (Head and Neck Oncology and Radiotherapy Group)
Debiopharm International SA
Eligible patients will be randomised to receive concomitant chemo-radiation therapy containing radiotherapy, Cisplatin and Debio 1143 (or a matched placebo) in Cycles 1-3, followed by Debio 1143 (or a matched placebo) monotherapy in Cycles 4-6.